These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9766617

  • 1. Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():28-34. PubMed ID: 9766617
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [Abstract] [Full Text] [Related]

  • 3. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G, Noisette C, Legrand A, Delahousse J.
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [Abstract] [Full Text] [Related]

  • 4. [Clozapine and treatment of negative symptoms].
    Lançon C, Farisse J, Llorca PM.
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [Abstract] [Full Text] [Related]

  • 5. Quetiapine has a direct effect on the negative symptoms of schizophrenia.
    Tandon R.
    Hum Psychopharmacol; 2004 Dec; 19(8):559-63. PubMed ID: 15486960
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M, Kuwilsky A, Krumm B, Dressing H.
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [Abstract] [Full Text] [Related]

  • 7. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A.
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [Abstract] [Full Text] [Related]

  • 8. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
    Nakanishi S, Kunugi H, Murray RM, Nojima S, Ogawa T, Takahashi T.
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
    [Abstract] [Full Text] [Related]

  • 9. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S.
    J Clin Psychiatry; 1999 Dec; 60 Suppl 23():5-9. PubMed ID: 10625193
    [Abstract] [Full Text] [Related]

  • 10. Pathophysiology and treatment of negative symptoms.
    Villeneuve A.
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [Abstract] [Full Text] [Related]

  • 11. Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group.
    Glick ID, Jacobs M, Lieberman J, Simpson G, Schooler NR.
    Psychopharmacol Bull; 1989 Nov; 25(3):344-7. PubMed ID: 2626513
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities.
    J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
    [Abstract] [Full Text] [Related]

  • 13. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey.
    Lecrubier Y, Perry R, Milligan G, Leeuwenkamp O, Morlock R.
    Eur Psychiatry; 2007 Sep; 22(6):371-9. PubMed ID: 17521890
    [Abstract] [Full Text] [Related]

  • 14. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G, Chong SA.
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [Abstract] [Full Text] [Related]

  • 15. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, Matsumoto N, Shinosaki K, Yoneda H, Kishimoto T, Kinoshita T.
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [Abstract] [Full Text] [Related]

  • 16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 17. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
    Gosselin O, Ribeyre JM, Kahn JP.
    Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
    [Abstract] [Full Text] [Related]

  • 18. [Remission of schizophrenic psychosis with negative symptoms with risperidone].
    Lübbe R.
    Fortschr Med; 1996 Feb 28; 114(6):35-6. PubMed ID: 8900527
    [Abstract] [Full Text] [Related]

  • 19. [Methodological constraints in evaluating anti-deficit effects].
    Boyer P, Lecrubier Y, Rein W.
    Encephale; 1996 Jun 28; 22 Spec No 2():25-7. PubMed ID: 8767038
    [Abstract] [Full Text] [Related]

  • 20. Clozapine, negative symptoms, and extrapyramidal side effects.
    Kane JM, Safferman AZ, Pollack S, Johns C, Szymanski S, Kronig M, Lieberman JA.
    J Clin Psychiatry; 1994 Sep 28; 55 Suppl B():74-7. PubMed ID: 7961579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.